A via receptor NMDA-óxido nítrico-GMP cíclico como alvo para o desenvolvimento de medicações antipsicóticas não-dopaminérgicas para a esquizofrenia by OLIVEIRA, João Paulo Maia de et al.
Schizophrenia is a devastating disorder that occurs in about 1% of 
the population worldwide. For over 30 years, it has been considered to 
be the result of dysfunctional brain dopaminergic pathways. However, 
dopaminergic antipsychotic drugs have proven effective for only some of 
the symptoms found in schizophrenia patients. Recent evidence suggests 
that dopaminergic abnormalities may be secondary to dysfunctions 
in multi-neurotransmitter systems modulating dopamine. One of 
the key neurotransmitters thought to be involved in schizophrenia 
is glutamate, and there is strong support for the involvement of a 
hypoactivity of N-methyl-D-aspartate (NMDA) glutamate receptors 
in the pathogenesis of schizophrenia. However, research with NMDA 
receptor agonists for the treatment of schizophrenia has produced 
inconsistent results, which may be due to the development of rapid 
tolerance to these compounds secondary to down-regulation of 
NMDA receptors. Perhaps the development of drugs that act on targets 
downstream NMDA receptors, such as nitric oxide (NO), could avoid 
the problem of the down-regulation of these receptors.
The NMDA-NO-cyclicGMP pathway
The activation of NMDA receptors by glutamate results in calcium 
influx into the cell; where calcium binds to calmodulin and stimulates 
the nNOS (neuronal nitric oxide synthase) enzyme to produce 
NO in the nervous system. Nitric oxide activates guanylate cyclase, 
which increases the production of cyclic GMP. This NMDA–NO–
cyclicGMP pathway has been shown to modulate the release of 
neurotransmitters such as glutamate and dopamine. Although the 
direction of these abnormalities is still under debate, this pathway has 
been consistently implicated in schizophrenia1.	
			
Nitric Oxide
NO is a gas that acts by mediating cellular communication in 
many ways in the nervous system. Its mechanism of action involves 
an increase in the concentrations of the second messenger cyclic 
GMP through activation of the soluble guanylate cyclase enzyme. 
NO is endogenously produced by the conversion of L-arginine 
into L-citrulline by NO synthase (NOS)2.
There are three known isoforms of NOS, namely the inducible form 
iNOS (expressed in macrophages, neutrophils, fibroblasts, vascular 
smooth muscles, and endothelial cells in response to pathological stimuli) 
and two forms called constitutive, which are present in the endothelium 
(eNOS) and neurons (nNOS) under normal physiologic conditions.
In the CNS, NO has been shown to influence the release of 
neurotransmitters, learning and memory, and neurodevelopment.
Therefore, growing evidence indicates that NO plays a 
predominant role in neuronal maturation and synaptogenesis 
during neuronal development. Thus, disturbances in NO release 
could interfere with both the maturation of cortical neurons and 
the formation of viable synaptic connections, in accordance with 
the neurodevelopmental hypothesis of schizophrenia.
Cyclic GMP
The stimulation of soluble guanylate cyclase by NO leads to 
increased synthesis of cGMP, a second messenger, which in turn 
influences the activity of kinase cascades, mRNA stability and 
translation, transcription factors and primary gene products in target 
cells. Some studies have reported an increase in cerebrospinal fluid 
levels of cyclic GMP in patients with schizophrenia after treatment 
with antipsychotic drugs3-5. As mentioned above, NO  increases 
the concentration of cyclic GMP through the activation of soluble 
guanylate cyclase. It is possible that this increase in cyclic GMP 
found in these three studies might be related to the stimulation 
by antipsychotic drugs of the NMDA–NO–cGMP pathway. We 
predict that the modulation of this pathway and increasing levels of 
NO in the CNS will be a productive target to pursue in the future 
development of antipsychotic drugs.  
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